Familial pancreatic cancer (FPC) status as a clinical biomarker in patients receiving platinum-based systemic therapy: A case-control analysis.

Deirdre Kelly,Ayelet Borgida,Sheron Perera,Robert E. Denroche,Spring Holter,Zhihui (Amy) Liu,Zijin Liu,Amy Zhang,Anna Dodd,Stephanie Ramotar,Shawn Hutchinson,Julie M. Wilson,Faiyaz Notta,Jennifer J. Knox,Steven Gallinger,Robert C. Grant,Grainne M. OKane

Familial pancreatic cancer (FPC) status as a clinical biomarker in patients receiving platinum-based systemic therapy: A case-control analysis.

2021

Deirdre Kelly
Ayelet Borgida
Sheron Perera
Robert E. Denroche
Spring Holter
Zhihui (Amy) Liu
Zijin Liu
Amy Zhang
Anna Dodd
Stephanie Ramotar
Shawn Hutchinson
Julie M. Wilson
Faiyaz Notta
Jennifer J. Knox
Steven Gallinger
Robert C. Grant
Grainne M. OKane

430Background: Familial pancreatic cancer (FPC) is broadly defined as kindreds with at least a pair of first-degree relatives with pancreatic ductal adenocarcinoma (PDA). The role of DNA damage res...

Keywords:

case control analysis
Oncology
Familial Pancreatic Cancer
pancreatic ductal adenocarcinoma
in patient
Internal medicine
DNA damage
clinical biomarker
Medicine
Systemic therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations